CYP 001
Alternative Names: Cymerus™ MSCs - Cynata Therapeutics; CYP-001; Mesenchymoangioblast-derived mesenchymal stem cells - Cynata TherapeuticsLatest Information Update: 22 Aug 2023
Price :
$50 *
At a glance
- Originator Cynata Therapeutics
- Class Induced pluripotent stem cell therapies; Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Graft-versus-host disease
- Phase I/II Adult respiratory distress syndrome; SARS-CoV-2 acute respiratory disease
Most Recent Events
- 14 Aug 2023 Phase-II clinical trials in Graft-versus-host disease in Australia (IV) (NCT05643638)
- 28 May 2022 No recent reports of development identified for phase-I development in Graft-versus-host-disease in Australia (IV, Infusion)
- 28 May 2022 No recent reports of development identified for phase-I development in Graft-versus-host-disease in United Kingdom (IV, Infusion)